{"idB": "1006281_18_item1_p147_s2", "idA": "1006281_17_item1_p138_s1", "sentA": "Assuming that the clinical data support the product s safety and effectiveness for its intended use, a new drug application, or NDA, or a BLA is submitted to the FDA for review.", "sentB": "BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA.", "type": 1, "words": ["<tag1>", "Assuming", "that", "the", "clinical", "data", "support", "the", "product", "s", "safety", "and", "effectiveness", "for", "its", "intended", "use,", "a", "new", "drug", "application,", "or", "NDA,", "or", "a", "BLA", "is", "submitted", "to", "the", "FDA", "for", "review.", "<tag2>", "BLA", "or", "NDA", "review", "usually", "does", "not", "begin", "until", "the", "drug", "company", "has", "submitted", "the", "entire", "application", "to", "the", "FDA.", "<tag3>"], "wordsA": ["Assuming", "that", "the", "clinical", "data", "support", "the", "product", "s", "safety", "and", "effectiveness", "for", "its", "intended", "use,", "a", "new", "drug", "application,", "or", "NDA,", "or", "a", "BLA", "is", "submitted", "to", "the", "FDA", "for", "review."], "wordsB": ["BLA", "or", "NDA", "review", "usually", "does", "not", "begin", "until", "the", "drug", "company", "has", "submitted", "the", "entire", "application", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p55_s1", "idA": "1006281_17_item1_p139_s0", "sentA": "Under the Orphan Drug Act of 1983, the FDA may grant orphan drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States.", "sentB": "It is a disease or condition associated with morbidity that has a substantial impact on survival, day-to-day function, and the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one.", "type": 1, "words": ["<tag1>", "Under", "the", "Orphan", "Drug", "Act", "of", "1983,", "the", "FDA", "may", "grant", "orphan", "drug", "designation", "to", "drugs", "and", "biological", "products", "intended", "to", "treat", "a", "rare", "disease", "or", "condition,", "which", "is", "generally", "a", "disease", "or", "condition", "that", "affects", "fewer", "than", "200,000", "individuals", "in", "the", "United", "States.", "<tag2>", "It", "is", "a", "disease", "or", "condition", "associated", "with", "morbidity", "that", "has", "a", "substantial", "impact", "on", "survival,", "day-to-day", "function,", "and", "the", "likelihood", "that", "the", "disease,", "if", "left", "untreated,", "will", "progress", "from", "a", "less", "severe", "condition", "to", "a", "more", "serious", "one.", "<tag3>"], "wordsA": ["Under", "the", "Orphan", "Drug", "Act", "of", "1983,", "the", "FDA", "may", "grant", "orphan", "drug", "designation", "to", "drugs", "and", "biological", "products", "intended", "to", "treat", "a", "rare", "disease", "or", "condition,", "which", "is", "generally", "a", "disease", "or", "condition", "that", "affects", "fewer", "than", "200,000", "individuals", "in", "the", "United", "States."], "wordsB": ["It", "is", "a", "disease", "or", "condition", "associated", "with", "morbidity", "that", "has", "a", "substantial", "impact", "on", "survival,", "day-to-day", "function,", "and", "the", "likelihood", "that", "the", "disease,", "if", "left", "untreated,", "will", "progress", "from", "a", "less", "severe", "condition", "to", "a", "more", "serious", "one."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p147_s1", "idA": "1006281_17_item1_p142_s1", "sentA": "For a fast track product, the FDA may consider for review on a rolling basis sections of the NDA or BLA before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA or BLA as they become available and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.", "sentB": "A drug candidate that receives Fast Track designation from the FDA is eligible for some or all of the following: more frequent meetings with the FDA to discuss the drug s development plan and ensure collection of appropriate data needed to support drug approval; more frequent written communication from the FDA about such things as the design of the proposed clinical trials; eligibility for the FDA s Accelerated Approval and Priority Review, if relevant criteria are met; and eligibility for Rolling Review, which allows a drug company to submit completed sections of its BLA or NDA for review by the FDA, rather than waiting until every section of the BLA or NDA is completed before the entire application can be reviewed.", "type": 1, "words": ["<tag1>", "For", "a", "fast", "track", "product,", "the", "FDA", "may", "consider", "for", "review", "on", "a", "rolling", "basis", "sections", "of", "the", "NDA", "or", "BLA", "before", "the", "complete", "application", "is", "submitted,", "if", "the", "sponsor", "provides", "a", "schedule", "for", "the", "submission", "of", "the", "sections", "of", "the", "NDA,", "the", "FDA", "agrees", "to", "accept", "sections", "of", "the", "NDA", "or", "BLA", "as", "they", "become", "available", "and", "determines", "that", "the", "schedule", "is", "acceptable,", "and", "the", "sponsor", "pays", "any", "required", "user", "fees", "upon", "submission", "of", "the", "first", "section", "of", "the", "NDA", "or", "BLA.", "<tag2>", "A", "drug", "candidate", "that", "receives", "Fast", "Track", "designation", "from", "the", "FDA", "is", "eligible", "for", "some", "or", "all", "of", "the", "following:", "more", "frequent", "meetings", "with", "the", "FDA", "to", "discuss", "the", "drug", "s", "development", "plan", "and", "ensure", "collection", "of", "appropriate", "data", "needed", "to", "support", "drug", "approval;", "more", "frequent", "written", "communication", "from", "the", "FDA", "about", "such", "things", "as", "the", "design", "of", "the", "proposed", "clinical", "trials;", "eligibility", "for", "the", "FDA", "s", "Accelerated", "Approval", "and", "Priority", "Review,", "if", "relevant", "criteria", "are", "met;", "and", "eligibility", "for", "Rolling", "Review,", "which", "allows", "a", "drug", "company", "to", "submit", "completed", "sections", "of", "its", "BLA", "or", "NDA", "for", "review", "by", "the", "FDA,", "rather", "than", "waiting", "until", "every", "section", "of", "the", "BLA", "or", "NDA", "is", "completed", "before", "the", "entire", "application", "can", "be", "reviewed.", "<tag3>"], "wordsA": ["For", "a", "fast", "track", "product,", "the", "FDA", "may", "consider", "for", "review", "on", "a", "rolling", "basis", "sections", "of", "the", "NDA", "or", "BLA", "before", "the", "complete", "application", "is", "submitted,", "if", "the", "sponsor", "provides", "a", "schedule", "for", "the", "submission", "of", "the", "sections", "of", "the", "NDA,", "the", "FDA", "agrees", "to", "accept", "sections", "of", "the", "NDA", "or", "BLA", "as", "they", "become", "available", "and", "determines", "that", "the", "schedule", "is", "acceptable,", "and", "the", "sponsor", "pays", "any", "required", "user", "fees", "upon", "submission", "of", "the", "first", "section", "of", "the", "NDA", "or", "BLA."], "wordsB": ["A", "drug", "candidate", "that", "receives", "Fast", "Track", "designation", "from", "the", "FDA", "is", "eligible", "for", "some", "or", "all", "of", "the", "following:", "more", "frequent", "meetings", "with", "the", "FDA", "to", "discuss", "the", "drug", "s", "development", "plan", "and", "ensure", "collection", "of", "appropriate", "data", "needed", "to", "support", "drug", "approval;", "more", "frequent", "written", "communication", "from", "the", "FDA", "about", "such", "things", "as", "the", "design", "of", "the", "proposed", "clinical", "trials;", "eligibility", "for", "the", "FDA", "s", "Accelerated", "Approval", "and", "Priority", "Review,", "if", "relevant", "criteria", "are", "met;", "and", "eligibility", "for", "Rolling", "Review,", "which", "allows", "a", "drug", "company", "to", "submit", "completed", "sections", "of", "its", "BLA", "or", "NDA", "for", "review", "by", "the", "FDA,", "rather", "than", "waiting", "until", "every", "section", "of", "the", "BLA", "or", "NDA", "is", "completed", "before", "the", "entire", "application", "can", "be", "reviewed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p4_s2", "idA": "1006281_17_item1_p24_s3", "sentA": "We also believe that the significant benefits of our ProCellEx system, if further substantiated in clinical trials and in the successful commercialization of taliglucerase alfa and our other product candidates, have the potential to transform the industry standard for the development of complex therapeutic proteins.", "sentB": "The COMP cited clinical and non-clinical justifications we provided to establish the significant benefit of pegunigalsidase alfa, noting that the COMP considered the justifications to constitute a clinically relevant advantage.", "type": 1, "words": ["<tag1>", "We", "also", "believe", "that", "the", "significant", "benefits", "of", "our", "ProCellEx", "system,", "if", "further", "substantiated", "in", "clinical", "trials", "and", "in", "the", "successful", "commercialization", "of", "taliglucerase", "alfa", "and", "our", "other", "product", "candidates,", "have", "the", "potential", "to", "transform", "the", "industry", "standard", "for", "the", "development", "of", "complex", "therapeutic", "proteins.", "<tag2>", "The", "COMP", "cited", "clinical", "and", "non-clinical", "justifications", "we", "provided", "to", "establish", "the", "significant", "benefit", "of", "pegunigalsidase", "alfa,", "noting", "that", "the", "COMP", "considered", "the", "justifications", "to", "constitute", "a", "clinically", "relevant", "advantage.", "<tag3>"], "wordsA": ["We", "also", "believe", "that", "the", "significant", "benefits", "of", "our", "ProCellEx", "system,", "if", "further", "substantiated", "in", "clinical", "trials", "and", "in", "the", "successful", "commercialization", "of", "taliglucerase", "alfa", "and", "our", "other", "product", "candidates,", "have", "the", "potential", "to", "transform", "the", "industry", "standard", "for", "the", "development", "of", "complex", "therapeutic", "proteins."], "wordsB": ["The", "COMP", "cited", "clinical", "and", "non-clinical", "justifications", "we", "provided", "to", "establish", "the", "significant", "benefit", "of", "pegunigalsidase", "alfa,", "noting", "that", "the", "COMP", "considered", "the", "justifications", "to", "constitute", "a", "clinically", "relevant", "advantage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p127_s0", "idA": "1006281_17_item1_p41_s3", "sentA": "In August 2014, the FDA approved Elelyso for injection for pediatric patients, and other jurisdictions, including Brazil, approved pediatric indications thereafter.", "sentB": "In 2017, the FDA approved the Supplemental New Drug Application (sNDA) we submitted to allow us to convert our manufacturing facility from a single dedicated product facility to a multi-product facility.", "type": 1, "words": ["<tag1>", "In", "August", "2014,", "the", "FDA", "approved", "Elelyso", "for", "injection", "for", "pediatric", "patients,", "and", "other", "jurisdictions,", "including", "Brazil,", "approved", "pediatric", "indications", "thereafter.", "<tag2>", "In", "2017,", "the", "FDA", "approved", "the", "Supplemental", "New", "Drug", "Application", "(sNDA)", "we", "submitted", "to", "allow", "us", "to", "convert", "our", "manufacturing", "facility", "from", "a", "single", "dedicated", "product", "facility", "to", "a", "multi-product", "facility.", "<tag3>"], "wordsA": ["In", "August", "2014,", "the", "FDA", "approved", "Elelyso", "for", "injection", "for", "pediatric", "patients,", "and", "other", "jurisdictions,", "including", "Brazil,", "approved", "pediatric", "indications", "thereafter."], "wordsB": ["In", "2017,", "the", "FDA", "approved", "the", "Supplemental", "New", "Drug", "Application", "(sNDA)", "we", "submitted", "to", "allow", "us", "to", "convert", "our", "manufacturing", "facility", "from", "a", "single", "dedicated", "product", "facility", "to", "a", "multi-product", "facility."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p5_s2", "idA": "1006281_17_item1_p50_s0", "sentA": "We believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth as there is a significant unmet medical need for Fabry disease treatments.", "sentB": "The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments.", "<tag2>", "The", "market", "exclusivity", "will", "not", "have", "any", "effect", "on", "Fabry", "disease", "treatments", "already", "approved", "at", "that", "time.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "treatment", "of", "Fabry", "disease", "is", "a", "specialty", "clinical", "niche", "with", "the", "potential", "for", "high", "growth", "as", "there", "is", "a", "significant", "unmet", "medical", "need", "for", "Fabry", "disease", "treatments."], "wordsB": ["The", "market", "exclusivity", "will", "not", "have", "any", "effect", "on", "Fabry", "disease", "treatments", "already", "approved", "at", "that", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p56_s1", "idA": "1006281_17_item1_p53_s0", "sentA": "In PRX-102, the prh-alpha-GALA, naturally occurring as a homodimer, is PEGylated and cross-linked to support and reinforce the homodimeric structure, which is crucial for the enzymatic activity of this enzyme.", "sentB": "The absence or reduction of this enzymatic activity leads to the progressive accumulation of glycolipids, especially Gb3, in capillary endothelial cells, podocytes, tubular cells, glomerular endothelial cells, mesangial cells, interstitial cells, cardiomyocytes, fibroblasts, and neurons.", "type": 1, "words": ["<tag1>", "In", "PRX-102,", "the", "prh-alpha-GALA,", "naturally", "occurring", "as", "a", "homodimer,", "is", "PEGylated", "and", "cross-linked", "to", "support", "and", "reinforce", "the", "homodimeric", "structure,", "which", "is", "crucial", "for", "the", "enzymatic", "activity", "of", "this", "enzyme.", "<tag2>", "The", "absence", "or", "reduction", "of", "this", "enzymatic", "activity", "leads", "to", "the", "progressive", "accumulation", "of", "glycolipids,", "especially", "Gb3,", "in", "capillary", "endothelial", "cells,", "podocytes,", "tubular", "cells,", "glomerular", "endothelial", "cells,", "mesangial", "cells,", "interstitial", "cells,", "cardiomyocytes,", "fibroblasts,", "and", "neurons.", "<tag3>"], "wordsA": ["In", "PRX-102,", "the", "prh-alpha-GALA,", "naturally", "occurring", "as", "a", "homodimer,", "is", "PEGylated", "and", "cross-linked", "to", "support", "and", "reinforce", "the", "homodimeric", "structure,", "which", "is", "crucial", "for", "the", "enzymatic", "activity", "of", "this", "enzyme."], "wordsB": ["The", "absence", "or", "reduction", "of", "this", "enzymatic", "activity", "leads", "to", "the", "progressive", "accumulation", "of", "glycolipids,", "especially", "Gb3,", "in", "capillary", "endothelial", "cells,", "podocytes,", "tubular", "cells,", "glomerular", "endothelial", "cells,", "mesangial", "cells,", "interstitial", "cells,", "cardiomyocytes,", "fibroblasts,", "and", "neurons."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p96_s2", "idA": "1006281_17_item1_p64_s4", "sentA": "All patients that completed the trial have opted to continue to receive 1 mg/kg of PRX-102 in an open-label extension trial, 60-month extension study under which all patients have been switched to receive 1 mg/kg of the drug, the selected dose for our phase III studies of PRX-102.", "sentB": "Currently, the first 14 patients have completed the study, and four patients are currently in treatment and follow-up.", "type": 1, "words": ["<tag1>", "All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102.", "<tag2>", "Currently,", "the", "first", "14", "patients", "have", "completed", "the", "study,", "and", "four", "patients", "are", "currently", "in", "treatment", "and", "follow-up.", "<tag3>"], "wordsA": ["All", "patients", "that", "completed", "the", "trial", "have", "opted", "to", "continue", "to", "receive", "1", "mg/kg", "of", "PRX-102", "in", "an", "open-label", "extension", "trial,", "60-month", "extension", "study", "under", "which", "all", "patients", "have", "been", "switched", "to", "receive", "1", "mg/kg", "of", "the", "drug,", "the", "selected", "dose", "for", "our", "phase", "III", "studies", "of", "PRX-102."], "wordsB": ["Currently,", "the", "first", "14", "patients", "have", "completed", "the", "study,", "and", "four", "patients", "are", "currently", "in", "treatment", "and", "follow-up."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p6_s0", "idA": "1006281_17_item1_p81_s0", "sentA": "In January 2017, we announced positive interim results from the phase IIa clinical trial for the first 13 CF patients enrolled in the study.", "sentB": "In January 2018, FDA granted Fast Track designation to PRX-102.", "type": 1, "words": ["<tag1>", "In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study.", "<tag2>", "In", "January", "2018,", "FDA", "granted", "Fast", "Track", "designation", "to", "PRX-102.", "<tag3>"], "wordsA": ["In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study."], "wordsB": ["In", "January", "2018,", "FDA", "granted", "Fast", "Track", "designation", "to", "PRX-102."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p71_s1", "idA": "1006281_17_item1_p81_s0", "sentA": "In January 2017, we announced positive interim results from the phase IIa clinical trial for the first 13 CF patients enrolled in the study.", "sentB": "Patients who did not continue in the extension trial included female patients who became or planned to become pregnant, and therefore were unable to continue in accordance with the study protocol, and patients that relocated to a location where treatment was not available under the clinical study.", "type": 1, "words": ["<tag1>", "In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study.", "<tag2>", "Patients", "who", "did", "not", "continue", "in", "the", "extension", "trial", "included", "female", "patients", "who", "became", "or", "planned", "to", "become", "pregnant,", "and", "therefore", "were", "unable", "to", "continue", "in", "accordance", "with", "the", "study", "protocol,", "and", "patients", "that", "relocated", "to", "a", "location", "where", "treatment", "was", "not", "available", "under", "the", "clinical", "study.", "<tag3>"], "wordsA": ["In", "January", "2017,", "we", "announced", "positive", "interim", "results", "from", "the", "phase", "IIa", "clinical", "trial", "for", "the", "first", "13", "CF", "patients", "enrolled", "in", "the", "study."], "wordsB": ["Patients", "who", "did", "not", "continue", "in", "the", "extension", "trial", "included", "female", "patients", "who", "became", "or", "planned", "to", "become", "pregnant,", "and", "therefore", "were", "unable", "to", "continue", "in", "accordance", "with", "the", "study", "protocol,", "and", "patients", "that", "relocated", "to", "a", "location", "where", "treatment", "was", "not", "available", "under", "the", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item1_p96_s7", "idA": "1006281_17_item1_p83_s0", "sentA": "Sputa available DNA samples were analyzed for approximately half of the patients in the phase II trial.", "sentB": "In addition, the majority of those patients show improvement in the study s additional efficacy endpoints, with 86% of the patients achieved an improvement in calprotectin, a protein biomarker present in the feces indicating intestinal inflammation, and 64% have an improved Geboes score, a histopathological scoring for the assessment of disease activity in ulcerative colitis.", "type": 1, "words": ["<tag1>", "Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients", "in", "the", "phase", "II", "trial.", "<tag2>", "In", "addition,", "the", "majority", "of", "those", "patients", "show", "improvement", "in", "the", "study", "s", "additional", "efficacy", "endpoints,", "with", "86%", "of", "the", "patients", "achieved", "an", "improvement", "in", "calprotectin,", "a", "protein", "biomarker", "present", "in", "the", "feces", "indicating", "intestinal", "inflammation,", "and", "64%", "have", "an", "improved", "Geboes", "score,", "a", "histopathological", "scoring", "for", "the", "assessment", "of", "disease", "activity", "in", "ulcerative", "colitis.", "<tag3>"], "wordsA": ["Sputa", "available", "DNA", "samples", "were", "analyzed", "for", "approximately", "half", "of", "the", "patients", "in", "the", "phase", "II", "trial."], "wordsB": ["In", "addition,", "the", "majority", "of", "those", "patients", "show", "improvement", "in", "the", "study", "s", "additional", "efficacy", "endpoints,", "with", "86%", "of", "the", "patients", "achieved", "an", "improvement", "in", "calprotectin,", "a", "protein", "biomarker", "present", "in", "the", "feces", "indicating", "intestinal", "inflammation,", "and", "64%", "have", "an", "improved", "Geboes", "score,", "a", "histopathological", "scoring", "for", "the", "assessment", "of", "disease", "activity", "in", "ulcerative", "colitis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
